Patent: 10,723,786
✉ Email this page to a colleague
Summary for Patent: 10,723,786
Title: | RSV-specific binding molecule |
Abstract: | The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided. |
Inventor(s): | Beaumont; Tim (Ouderkerk aan de Amstel, NL), Bakker; Adrianus Q. (Hoorn, NL), Yasuda; Etsuko (Amsterdam, NL) |
Assignee: | MedImmune, Limited (Cambridge, GB) |
Application Number: | 16/047,524 |
Patent Claims: | see list of patent claims |
Details for Patent 10,723,786
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | For Injection | 103770 | 06/19/1998 | ⤷ Try a Trial | 2029-10-06 |
Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | Injection | 103770 | 07/23/2004 | ⤷ Try a Trial | 2029-10-06 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |